Buckingham Strategic Partners Relay Therapeutics, Inc. Transaction History
Buckingham Strategic Partners
- $8.25 Billion
- Q3 2025
A detailed history of Buckingham Strategic Partners transactions in Relay Therapeutics, Inc. stock. As of the latest transaction made, Buckingham Strategic Partners holds 10,925 shares of RLAY stock, worth $72,323. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,925
Previous 11,162
2.12%
Holding current value
$72,323
Previous $38,000
50.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding RLAY
# of Institutions
216Shares Held
168MCall Options Held
714KPut Options Held
14.9K-
Sb Investment Advisers (Uk) LTD London, X027.9MShares$185 Million1.1% of portfolio
-
Commodore Capital LP New York, NY17MShares$113 Million5.66% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct14.8MShares$97.8 Million0.15% of portfolio
-
Casdin Capital, LLC New York, NY11.3MShares$75.1 Million8.07% of portfolio
-
Black Rock Inc. New York, NY10.5MShares$69.8 Million0.0% of portfolio
About Relay Therapeutics, Inc.
- Ticker RLAY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 120,219,000
- Market Cap $796M
- Description
- Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...